Vektor Medical, a US-based provider of AI-powered arrhythmia analysis technology, has unveiled results from two studies on its AI technologies in ventricular tachycardia (VT) analysis.
The company’s advanced technologies use AI and deep learning to evaluate wall thickness and scar tissue in VT patients and provide necessary insights for electrophysiologists.
The study results highlighted that Vektor’s AI technologies enhanced multimodal AI analysis for VT mapping and ablation.
The first study, Integration of Cloud-enabled AI Analyses of Ventricular Tachycardia Isthmuses with Electroanatomic Mapping Systems, combines ECG and CT data to provide VT analysis.
The study analysed ECGs of 31 ventricular tachycardia patients using computational mapping, which was then combined with corresponding CT scans on Vektor’s cloud-based platform.
In the study, a set of deep-learning models created detailed masks of cardiac chambers, meshes, and LV myocardial thicknesses, co-registered with ECG-localised VT exit sites.
The fused models were imported into electroanatomic mapping systems for generating accurate catheter guidance during VT ablation procedures.
The study showed that Vektor’s AI analysis of CT and 12-lead ECG provides a rapid, end-to-end solution for accurately localising VT isthmuses within scar tissue.
The method facilitated precise and efficient VT ablation, correlating with invasive activation mapping and VT termination sites, said the company.
The second study, dubbed Validation of a Deep Learning Ventricular Tachycardia Substrate Model, evaluated the AI algorithms in enhancing the analysis of myocardial wall thickness.
It is an emerging technique in identifying arrhythmogenic tissue underlying VT, said Vektor.
The company’s AI-based process used raw CT scans to create a three-dimensional (3D) wall-thinning heart model, accurately segmenting cardiac structures in 31 VT patients with various heart morphologies and imaging artifacts.
In the study, the AI model achieved high accuracy in segmenting cardiac structures in VT patients, with wall thinning measurements aligning closely with invasive substrate mapping.
Vektor Medical CEO Rob Krummen said: “AI technology has long promised to revolutionise healthcare, and today, we’re seeing that promise become reality.
“The results of these studies underscore how Vektor Medical continues to push the boundaries of what is possible with AI in arrhythmia care. I’m incredibly proud of our team for earning two of the top five abstracts at HRX 2024.
“Our company is committed to streamlining procedures, enhancing clinical efficiency, and, above all, improving patient outcomes. We are excited to share these findings with the passionate professionals dedicated to transforming healthcare at HRX 2024.”
